Royalty Pharma Sub-Manager, LLC

Est. AUM

$172.8M

13F long equity, this entity only

Positions

Period

Mar 2026 (Q1)

SEC EDGAR

Mar 2026 (Q1)

#	Issuer	Class	Value	Shares	% Portfolio	Discretion
1	CYTOKINETICS, INC	COM	$64.6M	980392	37.40%	DFND
2	ZENAS BIOPHARMA, INC.	COM	$46.7M	2388150	27.02%	DFND
3	BIOCRYST PHARMACEUTICALS INC	COM	$36.6M	3846154	21.19%	DFND
4	BIOHAVEN LTD	COM	$24.8M	2936507	14.38%	DFND

Values in USD (reported in $thousands on 13F). Source: SEC EDGAR.